GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (STU:1AEA) » Definitions » Cyclically Adjusted Revenue per Share

argenx SE (STU:1AEA) Cyclically Adjusted Revenue per Share : €7.90 (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is argenx SE Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

argenx SE's adjusted revenue per share for the three months ended in Dec. 2024 was €10.588. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €7.90 for the trailing ten years ended in Dec. 2024.

During the past 12 months, argenx SE's average Cyclically Adjusted Revenue Growth Rate was 80.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2025-05-10), argenx SE's current stock price is €505.00. argenx SE's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2024 was €7.90. argenx SE's Cyclically Adjusted PS Ratio of today is 63.92.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of argenx SE was 171.16. The lowest was 52.50. And the median was 87.96.


argenx SE Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for argenx SE's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Cyclically Adjusted Revenue per Share Chart

argenx SE Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 2.49 4.41 7.90

argenx SE Quarterly Data
Sep19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.41 5.12 6.07 6.75 7.90

Competitive Comparison of argenx SE's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, argenx SE's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


argenx SE's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, argenx SE's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where argenx SE's Cyclically Adjusted PS Ratio falls into.


;
;

argenx SE Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, argenx SE's adjusted Revenue per Share data for the three months ended in Dec. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=10.588/131.6300*131.6300
=10.588

Current CPI (Dec. 2024) = 131.6300.

argenx SE Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201409 0.099 99.960 0.130
201412 0.092 99.050 0.122
201503 0.077 99.750 0.102
201506 0.098 100.230 0.129
201509 0.146 100.500 0.191
201512 0.110 99.730 0.145
201603 0.143 100.310 0.188
201606 0.168 100.260 0.221
201609 0.245 100.570 0.321
201612 0.173 100.710 0.226
201703 0.256 101.440 0.332
201706 0.615 101.370 0.799
201709 0.240 102.030 0.310
201712 0.271 101.970 0.350
201803 0.172 102.470 0.221
201806 0.365 103.100 0.466
201809 0.058 103.950 0.073
201812 0.035 103.970 0.044
201903 0.913 105.370 1.141
201906 0.199 105.840 0.247
201909 0.183 106.700 0.226
201912 0.469 106.800 0.578
202006 0.000 107.510 0.000
202012 0.000 107.850 0.000
202103 2.660 108.870 3.216
202106 4.466 109.670 5.360
202109 0.014 110.790 0.017
202112 0.447 114.010 0.516
202203 0.408 119.460 0.450
202206 1.298 119.050 1.435
202209 2.524 126.890 2.618
202212 2.969 124.940 3.128
202303 3.684 124.720 3.888
202306 4.473 125.830 4.679
202309 5.316 127.160 5.503
202312 6.308 126.450 6.566
202403 6.220 128.580 6.368
202406 7.459 129.910 7.558
202409 7.854 131.610 7.855
202412 10.588 131.630 10.588

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


argenx SE  (STU:1AEA) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

argenx SE's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=505.00/7.90
=63.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of argenx SE was 171.16. The lowest was 52.50. And the median was 87.96.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


argenx SE Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of argenx SE's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


argenx SE Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (STU:1AEA) » Definitions » Cyclically Adjusted Revenue per Share
Address
Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

argenx SE Headlines

No Headlines